Clinical Ink has pioneered the development of eSource technology for use in clinical trials. The company's innovative approach has been recognized by the Society of Clinical Data Management, Microsoft, and Gartner Research as having 'significant disruptive potential' to transform the current clinical trial business model. SureSource™ replaces paper source documents and CRFs with intuitive electronic forms that maintain the natural workflow, ease of use, and mobility of paper charts. Unlike EDC systems, the Company's approach to eSource captures/validates data during the subject visit. As a result, data queries are dramatically reduced, SDV is eliminated, monitoring is performed real-time and remotely, and validated clinical data is available within minutes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/16/13 | $4,300,000 | Series B |
FCA Venture Partners | undisclosed |
| 03/19/15 | undisclosed | Growth |
FCA Venture Partners MPM Capital | undisclosed |
